ASH 2022: Multiple myeloma roundup

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML

Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not have worse short-term recurrence rates

Comment: POLAR gene profile can identify which patients can safely avoid radiation therapy after breast-conserving surgery

Updates from TAILORx and RxPONDER: Implications for practice

Interruption of endocrine therapy in young breast cancer patients does not increase the risk of short-term relapse

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL

Longest follow-up of patients with early breast cancer shows radiotherapy does not improve survival after 30 years

Maximising cancer treatment and research through omics, data sharing, and open science

Epidemiology, detection, and management of NAFLD: a Latin American perspective

Optimisation of supportive, palliative and end of life care

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma